Latest News

Are you wondering if Global Industrial still offers good value after its recent run, or if the current price already reflects the key positives for the business? The stock last closed at US$33.26, with returns of 4.3% over 7 days, 9.9% over 30 days, 13.1% year to date, 48.4% over 1 year, 32.6% over 3 years and 10.4% over 5 years. This naturally raises questions about what is now priced in. Recent coverage has focused on Global Industrial's role as a distributor of industrial and business...

Cromwell Property Group (ASX:CMW) has posted its H1 2026 numbers with total revenue of A$88.2 million and basic EPS of A$0.00145, giving investors a fresh datapoint on how the office focused REIT is tracking. The group has seen recent revenue move from A$97.9 million in H2 2024 to A$94.4 million in H1 2025 and then A$88.2 million in H2 2025. Basic EPS shifted from a loss of A$0.037802 per share in H2 2024 to a loss of A$0.041925 in H1 2025 and then a small profit of A$0.00145 in H2 2025. For...

Axsome Therapeutics (NasdaqGM: AXSM) has started the CLARITY Phase 3 trial of solriamfetol in major depressive disorder with excessive daytime sleepiness. The trial focuses on a group of MDD patients who experience excessive daytime sleepiness, for which no approved treatments are currently available. This study expands Axsome's clinical program into an area of unmet medical need. Axsome Therapeutics, listed on the NasdaqGM under the ticker AXSM, develops therapies for central nervous...

SPX Technologies is pursuing an acquisition-led expansion and investing heavily in capacity, including in data center infrastructure. The company recently reported record earnings that align with this repositioning of its business mix. At the same time, insider selling and shifts in institutional ownership are reshaping who holds NYSE:SPXC shares. For investors, this mix of corporate activity and ownership changes makes NYSE:SPXC a stock to watch. The shares recently closed at $231.59, with...

Buy-back puts Dyno Nobel (ASX:DNL) capital management in focus Dyno Nobel (ASX:DNL) is in the spotlight after continuing its on-market share buy-back, with more than 34 million ordinary shares already repurchased as part of its ongoing capital management program. See our latest analysis for Dyno Nobel. The on market buy back comes as Dyno Nobel’s share price sits at A$3.32, with a 1 month share price return of a 6.21% decline but a 1 year total shareholder return of 25.30%, indicating longer...

Heartland Group Holdings (NZSE:HGH) has released fresh numbers for H1 2026, reporting H2 2025 revenue of $146.2 million, basic EPS of $0.036, and net income of $35.2 million, set against trailing 12 month revenue of $308.7 million and EPS of $0.088. The company’s revenue increased from $124.9 million in H2 2024 to $146.2 million in H2 2025, while trailing 12 month net income reached $84.0 million, giving investors a clearer view of how earnings are tracking into the new half. Overall, the...

Macmahon Holdings (ASX:MAH) has drawn fresh attention after reporting higher half year revenue of A$1,310.53 million, increased net income of A$48.21 million, a higher interim dividend, and reaffirmed its FY26 earnings guidance. See our latest analysis for Macmahon Holdings. While the latest results and higher interim dividend have caught investors’ attention, Macmahon’s 30 day share price return of 7.19% and 90 day share price return of 28.45% build on very large 1 year and 3 year total...

Loblaw Companies (TSX:L) has just posted its FY 2025 third quarter numbers, with revenue of C$19.4b, basic EPS of C$0.67 and net income of C$794m, while same store sales growth came in at 2%. The company has seen quarterly revenue move from C$14.1b and EPS of C$0.42 in Q1 2025 to C$14.7b and C$0.60 in Q2 2025, alongside trailing twelve month EPS of C$2.13 on C$63.9b of revenue. This sets up a story where improving margins and earnings power are front and center for investors parsing this...

Waypoint REIT (ASX:WPR) has put fresh numbers on the table for FY 2025, with first half revenue of A$178.3 million and basic EPS of A$0.20, setting the tone for how investors assess the latest period. The trust has seen revenue move from A$118.2 million and EPS of A$0.14 in the first half of 2024 to A$178.3 million and EPS of A$0.20 in the first half of 2025. The trailing twelve month EPS sits at A$0.30 on revenue of A$162.8 million for the most recent half, giving investors a fuller view of...

NOVONIX FY 2025 earnings snapshot NOVONIX (ASX:NVX) opened FY 2025 with first half revenue of about US$2.8 million and a basic EPS loss of US$0.03, while net income excluding extras came in at a loss of roughly US$20.1 million. Over recent periods the company has seen revenue move from about US$2.7 million in 1H FY 2024 to US$3.1 million in 2H FY 2024 and back to US$2.8 million in 1H FY 2025. EPS losses have ranged between US$0.06 and US$0.09 before the latest US$0.03 result. The market will...

Actinogen Medical (ASX:ACW) has reported its H1 2026 numbers with trailing twelve month revenue of A$7.4 million and a basic EPS loss of A$0.0058 per share, keeping the focus firmly on how much cash the business is consuming rather than generating. The company has seen reported half year revenue move between A$9.0 million in H2 2024, A$0 in H1 2025 and A$5.5 million in H2 2025, alongside basic EPS losses of A$0.0007, A$0.0028 and A$0.0022 respectively, so investors are likely to be weighing...

COG Financial Services (ASX:COG) has put fresh numbers on the table for H1 2026, with trailing 12 month revenue of A$383.5 million, net income of A$20.2 million and basic EPS of A$0.099, set against a share price of A$1.54. The company has seen revenue move from A$367.7 million to A$383.5 million over recent trailing 12 month periods, while basic EPS shifted from A$0.094 to A$0.099 across the same TTM snapshots. This sets up a results season where margins and earnings quality are front and...

Why these new NHS cloud deals matter for Sectra (OM:SECT B) Sectra (OM:SECT B) has expanded its managed cloud imaging presence in the UK, signing multi year contracts with several NHS trusts that indicate a growing base of recurring service revenue. See our latest analysis for Sectra. These NHS cloud wins arrive after a difficult stretch for the shares, with a 30 day share price return of a 16.45% decline and a 90 day share price return of a 34.68% decline. This comes even though the 3 year...

RAM Essential Services Property Fund (ASX:REP) has just posted its H1 2026 scorecard, with trailing twelve month revenue at A$58.0 million and net income of A$4.8 million, while Funds From Operations sits at A$24.5 million, giving investors a clear read on its cash generation profile. The fund has seen revenue move from A$40.3 million in H2 2024 to A$41.0 million in H2 2025 on a half year basis, as FFO shifted from A$22.8 million to A$16.9 million over the same periods, setting up a picture...

Bapcor (ASX:BAP) has reported a challenging H1 2026, with revenue of A$973.0 million and a basic EPS loss of A$0.31 tied to net income of A$104.8 million in the red. Over the last three reported halves, revenue has moved from A$1,012.4 million in H1 2025 to A$963.4 million in H2 2025 and A$973.0 million in H1 2026. Over the same periods, EPS shifted from a profit of A$0.11 in H1 2025 to a loss of A$0.04 in H2 2025 and a deeper loss of A$0.31 in the latest half. This sets up a results season...

Earnings jump and dividend reset put focus on Perpetual’s trade offs Perpetual (ASX:PPT) has drawn fresh attention after reporting half year sales of A$704.1 million and net income of A$53.9 million, alongside a lower ordinary dividend of A$0.59 per share. The result, which also included higher basic and diluted earnings per share from continuing operations compared with a year earlier, sits alongside an announced ordinary unfranked dividend payable on 7 April 2026, with a March ex date and...

29Metals (ASX:29M) has kicked off FY 2025 with first half revenue of A$271.0 million and basic EPS of A$0.026, with trailing twelve month revenue at A$566.6 million and EPS at A$0.018 as the business shifts back into profit on a full year basis. Over the past year, the company has seen revenue move from A$551.1 million to A$566.6 million on a trailing basis, while net income has turned from a A$177.6 million loss to a A$24.2 million profit. This signals a clear reset in earnings power and...

Appen (ASX:APX) has put fresh numbers on the table, pairing its 2025 full year result with a new 2026 revenue outlook of US$270 million to US$300 million, giving investors updated earnings context. See our latest analysis for Appen. The new guidance appears to have landed in the middle of a sharp re‑rating, with Appen’s 30 day share price return of 72.69% and 90 day share price return of 160.84% contrasting with a 5 year total shareholder return decline of 86.48%. This suggests recent...

Clinuvel Pharmaceuticals (ASX:CUV) has put out its H1 2026 scorecard with investors looking closely at the recent revenue and EPS trends relative to its trailing performance. The company has seen total revenue move from A$55.4 million in H2 2024 to A$59.4 million in H2 2025, while basic EPS shifted from A$0.49 to A$0.44 over the same halves. This sets the backdrop for trailing 12 month figures that include revenue of A$96.9 million and basic EPS of A$0.65. With trailing net profit margins...

Betr Entertainment (ASX:BBT) has reported H1 2026 revenue of A$68.9 million with a net loss of A$32.7 million, equal to basic EPS of A$0.031, setting a clear earnings season marker for investors watching the betting and entertainment space. The company has seen first half revenue move from A$27.8 million in 2024 to A$68.9 million in 2025, while basic EPS shifted from A$0.0517 to A$0.031 and net loss widened from A$10.4 million to A$32.7 million over the same halves. The latest numbers are...

Ultragenyx Pharmaceutical (NasdaqGS:RARE) announced that the US FDA has accepted its Biologics License Application for DTX401, a gene therapy for Glycogen Storage Disease Type Ia. The FDA has granted Priority Review to the application, signaling an expedited assessment timeline. If approved, DTX401 could become the first pharmacologic treatment option for people living with Glycogen Storage Disease Type Ia. For Ultragenyx, with a current share price of $23.04, this regulatory milestone...

IDEXX Laboratories (NasdaqGS:IDXX) announced the upcoming retirement of long-serving Board member M. Anne Szostak. The company also disclosed the appointment of Michael G. Erickson, PhD, to its Board of Directors. These Board changes reflect an ongoing refresh of corporate governance and Board composition. IDEXX Laboratories focuses on diagnostic and software solutions for veterinary practices, livestock, poultry, and water testing, placing the company at the center of long term trends in...

If you are wondering whether Shionogi's current share price really reflects its underlying worth, this article will walk through what the numbers are saying about value. Shionogi's share price recently closed at ¥3,648, with returns of 0.2% over 7 days, 15.8% over 30 days, 27.3% year to date, 62.2% over 1 year, 97.4% over 3 years and 124.6% over 5 years. This performance has put the stock firmly on many investors' radars. Recent headlines around Shionogi have kept attention on the company...

In February 2026, Aspen Aerogels reported fourth-quarter 2025 sales of US$41.34 million versus US$123.09 million a year earlier, swung to a net loss of US$72.91 million, recorded an impairment charge on property, plant and equipment, and launched a broad review of options for its business and capital structure. An important insight is that management characterizes this strategic review as coming from a position of financial strength and operational progress, even as the company posts a...